For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)
Por um escritor misterioso
Descrição
Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.
Targets, trials and tribulations in Alzheimer therapeutics
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for
Alzheimer's Disease Insight Report: Current Therapies, Drug
FDA Approves First Drug to Treat Agitation Symptoms Associated
BioXcel shares rise on result of Alzheimer's drug probe
Bioxcel shares plunge on FDA warning letter despite promising data
Leqembi Granted Full FDA Approval to Treat Early Alzheimer's Disease
SLU Researcher Finds Help for Alzheimer's-Associated Agitation
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for
JAMA Neurology Publishes Complete Results of Positive Phase 3
Pharma News for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka
Otsuka Pharmaceutical and Lundbeck present positive results
Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation
de
por adulto (o preço varia de acordo com o tamanho do grupo)
